| |
|
|
|
Xtalks, Online
2024-07-30
In this webinar, the expert speakers will focus on the reasons for the increase in demand for radiopharmaceuticals and dosimetry for tailoring cancer treatment; current challenges in clinical trials and deficiencies presented in the current dosimetry regulatory guidelines and protocols; and advancements in routine clinical dosimetry driven by emerging technologies such as artificial intelligence (AI)-driven dosimetry methods.
While the trajectory of radiopharmaceutical dosimetry is promising, challenges persist within the clinical trial landscape. Deficiencies in existing guidelines from regulatory bodies such as the US Food and Drug Administration (FDA), European Association of Nuclear Medicine (EANM) and Foundation for the National Institutes of Health (FNIH) pose hurdles that need addressing.
For cancer treatment, the growing interest in radiopharmaceuticals and dosimetry is evident. The increasing demand for personalized medicine applications and their impact on clinical outcomes suggests a rising need for tailored dosage and treatment for each patient’s cancer profile.
Register today to gain insights into clinical trials of radiopharmaceuticals and the possibility of AI-driven dosimetry methods in the future.
Keywords: Cancer, Drug Development, Precision Medicine, Clinical Research, CRO, Oncology, Therapeutic Areas, Artificial Intelligence, AI, Radiopharmaceuticals, Radiation Oncology, Radiopharmaceutical, Precision Oncology, Toxicology/Safety
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Jon DeVries, MBA, Chief Executive Officer, Mirada Medical
Mark Crockett, MD, Chief Medical Officer, Mirada Medical; President, TeleDaaS
Jess Guarnaschelli, MD, Senior Medical Director, Medical Department, Medpace
Daphnée Villoing, PhD, Dosimetry Specialist and Senior Project Manager, Medpace Core Labs
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2024-07-30
|
|
|
|
|
|
|
|
Registration:
|
|
Free Registration
|
|
|
E-mail:
|
|
tristan@xtalks.com
|
|
|
|
|
|
|
|
|